January 30, 2023
Deka Biosciences ("Deka"), a biotech company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the investigational new drug (IND) application for DK210 (EGFR) and concluded that Deka may proceed with a Phase 1 clinical trial in the United States.
Read More
December 12, 2022
Is Hollywood moving to the prairie? Omar Villafranca takes a look at how Oklahoma state incentives are bringing motion-picture production to the state.
Read More
